Evidence map›Paper›PMID 22039251›Full record

Trial reportInvestigative ophthalmology & visual science2011

New grading criteria allow for earlier detection of geographic atrophy in clinical trials.

Hilary Smolen Brader, Gui-Shuang Ying, E Revell Martin, Maureen G Maguire, Complications of Age-Related Macular Degeneration Prevention Trial-CAPT Research Group

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Investigative ophthalmology & visual science, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00000167 (Complications of Age-Related Macular Degeneration Prevention Trial), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000167 phase3completednot on this map

Complications of Age-Related Macular Degeneration Prevention Trial (CAPT)

TypeinterventionalSponsorNational Eye Institute (NEI)Ran1999 to 2006Enrolled1,052ConditionsMacular DegenerationArmsLow-Intensity Laser Treatment
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Optical imaging of the chorioretinal vasculature in the living human eye.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hilary Smolen BraderScheie Eye Institute, Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania 19104-3309, USA. hilary.brader@uphs.upenn.edu
Gui-Shuang Ying
E Revell Martin
Maureen G Maguire
Complications of Age-Related Macular Degeneration Prevention Trial-CAPT Research Group
Penn Presbyterian Medical Center · US

Funding

COORDINATING CENTER FOR AMD PREVENTION TRIALU10EY012279 · NEI · UNIVERSITY OF PENNSYLVANIA · PI MAGUIRE, MAUREEN G · 1999 to 2006
$14.9M
READING CENTER FOR AMD PREVENTION TRIALU10EY012211 · NEI · UNIVERSITY OF PENNSYLVANIA · PI FINE, STUART · 1999 to 2006
$2.9M
AGE-RELATED MACULAR DEGENERATION PREVENTION TRIALU10EY012261 · NEI · UNIVERSITY OF PENNSYLVANIA · PI FINE, STUART L · 1999 to 2006
$859k
NEI NIH HHS EY012211NEI NIH HHS EY012261NEI NIH HHS EY012279NEI NIH HHS U10 EY012211NEI NIH HHS U10 EY012261NEI NIH HHS U10 EY012279
6 · The paper itself

Abstract

purposeTo evaluate new grading criteria for geographic atrophy (GA), as detected by annual stereoscopic color fundus photographs and fluorescein angiograms, and to assess whether application of the revised criteria provides earlier identification of GA than previous criteria involving only color fundus photography.

methodsAnnual fundus image sets from 114 CAPT patients who developed GA in the untreated eye during 5 to 6 years of follow-up were reassessed for the presence of GA, using revised grading criteria, in which GA was defined by (1) the presence of hyperfluorescence on fluorescein angiography; and (2) at least one other characteristic indicative of involution of the retinal pigment epithelium (i.e., sharp edges, excavation of the retina, or visible choroidal vessels on either color images or fluorescein angiograms). Reliability and time of initial detection of GA using the revised criteria were assessed.

resultsThe revised criteria are reliable (97.8% intragrader, 93.3% intergrader agreement) and accurate (false-positive rate, 0.8%) for detecting individual early GA lesions. Using this revised method, individual GA lesions were identified 1-year earlier on average than was possible with criteria used in previous CFP studies. The use of two imaging modalities was more sensitive in detecting GA and its features than either imaging modality alone (P ≤ 0.0001).

conclusionsEarly GA areas can be reliably identified when defining criteria are based on both color photographs and fluorescein angiograms. These methods can be used to investigate the natural history of GA earlier in the course of disease than previously possible and to facilitate the design of future clinical trials of treatments for GA. (ClinicalTrials.gov number, NCT00000167).

Indexed as

False Positive ReactionsFluorescein AngiographyFollow-Up StudiesGeographic AtrophyHumansLaser CoagulationObserver VariationPredictive Value of TestsReproducibility of ResultsTime FactorsVision DisordersVisual Acuity

Identifiers

PMID22039251
PMCPMC3302429
OpenAlexW2069840972

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.